---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-26-000022"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:21:50.603519+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges

## Summary
- Product sales ex-Veklury $6.8B (+8% YoY); HIV sales $5.0B (+10%); Biktarvy $3.4B (+7%).
- GAAP diluted EPS $1.61 (vs $1.04); non-GAAP $2.03 (vs $1.81) — both up YoY.
- Full-year product sales guidance raised to $30.0-30.4B; GAAP EPS guidance cut to $(3.25)-(2.85) from $6.75-7.15.
- EPS guidance reduction driven by anticipated $11.5B IPR&D charges for Arcellx, Ouro and Tubulis acquisitions.
- Cell Therapy sales down 12% to $407M; Trodelvy up 37% to $402M; Veklury down 52% to $144M.

## SEC filing metadata
- accession: 0000882095-26-000022
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/0000882095-26-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/gild-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-26-000022
- JSON: https://secwatch.observer/filing/0000882095-26-000022.json
- Plain text: https://secwatch.observer/filing/0000882095-26-000022.txt

## Source-grounded claims
- claim_id: c975486349857142edf24b0ee7ec008b5a17f87a
  claim: GILEAD SCIENCES, INC. reported first quarter 2026 results: revenue $7.0 billion, EPS $1.61. Guidance raised.
  evidence_excerpt: in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/0000882095-26-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.